Human Urine Sample Collection for Alport Nephropathy Biomarker Studies

Terminated

• Conditions: Alport Syndrome

• Registration Number: NCT01602835
• Lead Sponsor: Novartis Pharmaceuticals

Brief Summary

This is a prospective cross-sectional, observational, single-center study of Alport patients, in which a single, first morning voided urine collection will be acquired and used to validate assays of urine biomarkers that reflect changes in glomerular protein filtration barrier function.

The purpose of this study is to identify biomarkers indicative of changes in glomerular filtration function that occur during the course of proteinuric renal diseases such as Alport nephropathy.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2012-05-17
• Study First Submitted QC: 2012-05-18
• Study First Posted: 2012-05-21
• Study Start: 2012-09
• Primary Completion: 2013-05
• Study Completion: 2013-05
• Status Verified: 2014-02
• Last Update Submitted: 2014-02-10
• Last Update Posted: 2014-02-11

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified